AstraZeneca's Definiens rolls out biomarker data service

Definiens introduced a suite of services to help companies gather data from tissue samples and use the resource to identify potential companion diagnostics. The company, which was acquired by AstraZeneca's ($AZN) MedImmune late last year, views the service as a way for oncology drug developers to pick the strongest biomarker signals to advance into clinical development. Release

Suggested Articles

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.

TriNetX's platform uses EHR data to help drug developers with clinical trial protocol design and study site and participant identification.

The $58 million financing round represents biopharma industry's growing interest in genomics data.